Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis

by Laura C. Cappelli, Maximilian F. Konig, Allan C. Gelber, Clifton O. Bingham, Erika Darrah
Published 2018-03-01

Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps

by Laura C. Cappelli, Suzanne M. Grieb, Ami A. Shah, Clifton O. Bingham, Ana-Maria Orbai
Published 2020-08-01

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis

by Erika Darrah, Jon T. Giles, Ryan L. Davis, Pooja Naik, Hong Wang, Maximilian F. Konig, Laura C. Cappelli, Clifton O. Bingham, Sonye K. Danoff, Felipe Andrade
Published 2018-11-01

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series

by Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman, Laura C. Cappelli
Published 2018-10-01

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry...

by Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh
Published 2021-03-01

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

by Rajeev Sharma, Laura C Cappelli, Michelle Turner, Julie R Brahmer, Paolo Antonio Ascierto, Hamzah Abu-Sbeih, Jeffrey A Sosman, Jill Brufsky, Mario E Lacouture, Lamya Hamad, Miguel-Angel Perales, Eric Hansen, David E Gerber, Frank B Cortazar, Gregory A Masters, Michele Nanni, Satish P Shanbhag, Dimitra Skondra
Published 2021-06-01